Replies to post #1016 on RedHill Biopharma Ltd (RDHL)

[Amatuer17]

Look at yesterday's report.
All trials going well but they are long term - none of the approval will come in 2018.

So only the 2 products will give some revenue. If you read the announcements at the time of deal - the yearly revenue at peak is not very large - only in few millions - in teens

I am afraid - unless there is partnership or BO - this stock will remain below 10 and when overall market turns bad - this will deep faster giving better buying opportunity.

They are spending high amount of funds on many big trials.

H priori trial - 65 sites - 400+ patients - at least 1 year - so filing cannot be before Q1-2019